MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Amneal Pharmaceuticals Gross Profit 2011-2026 | AMRX
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Amneal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.11 B | 1.02 B | 821 M | 785 M | 769 M | 628 M | 353 M | 716 M | 526 M | 597 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 B | 353 M | 733 M |
Quarterly Gross Profit Amneal Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 274 M | 286 M | 256 M | 270 M | 250 M | 238 M | 233 M | 220 M | 178 M | - | 194 M | 201 M | 175 M | - | 199 M | 212 M | 192 M | - | 134 M | 144 M | 183 M | 110 M | 54.4 M | 105 M | 83.1 M | 193 M | 200 M | 178 M | 145 M | 151 M | 135 M | 124 M | 116 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 286 M | 54.4 M | 181 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M |  USA |
 |
Altimmune
ALT
|
8.18 K | $ 4.2 | -2.67 % | $ 298 M | USA |
 |
Aptorum Group Limited
APM
|
-104 K | $ 0.8 | 1.87 % | $ 4.36 M |  China |
 |
Aptevo Therapeutics
APVO
|
4.31 M | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
Aquestive Therapeutics
AQST
|
32.9 M | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
9.54 M | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
4.68 M | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
argenx SE
ARGX
|
2.68 M | $ 756.71 | -1.33 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
823 K | $ 10.91 | 1.58 % | $ 394 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arrowhead Pharmaceuticals
ARWR
|
147 K | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Ascendis Pharma A/S
ASND
|
625 M | $ 231.56 | -0.83 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.39 | -1.63 % | $ 8.16 B |  Australia |
 |
Atossa Therapeutics
ATOS
|
-131 K | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
-52.5 M | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
1.24 B | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Aytu BioScience
AYTU
|
45.8 M | $ 2.56 | -0.58 % | $ 16.1 M | USA |